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The series of events leading to tertiary lymphoid organ (TLO)
formation in mucosal organs following tissue damage remain
unclear. Using a virus-induced model of autoantibody formation in
the salivary glands of adult mice, we demonstrate that IL-22
provides a mechanistic link between mucosal infection, B-cell
recruitment, and humoral autoimmunity. IL-22 receptor engage-
ment is necessary and sufficient to promote differential expression
of chemokine (C-X-C motif) ligand 12 and chemokine (C-X-C motif)
ligand 13 in epithelial and fibroblastic stromal cells that, in turn, is
pivotal for B-cell recruitment and organization of the TLOs.
Accordingly, genetic and therapeutic blockade of IL-22 impairs
and reverses TLO formation and autoantibody production. Our
work highlights a critical role for IL-22 in TLO-induced pathology
and provides a rationale for the use of IL-22–blocking agents in
B-cell–mediated autoimmune conditions.
IL-22 | tertiary lymphoid organs | chemokines | Sjogren’s syndrome |
autoimmunity
Tertiary lymphoid organs (TLOs) are organized clusters ofimmune cells that preferentially form in autoimmune dis-
eases such as Sjogren’s syndrome and Hashimoto thyroiditis (1).
TLOs’ cellular compartments, spatial organization, vasculature,
and function are similar to those of secondary lymphoid organs
(SLOs), providing a local hub for autoreactive B-cell pro-
liferation and affinity maturation. TLOs appear to contribute to
disease progression and to the emergence of malignant B clones
responsible for lymphoma development (2). Within TLOs, the
ectopic expression of lymphoid chemokines has been shown to
correlate with the size or degree of organization of lymphoid
aggregates and with the production of autoantibodies (3, 4). In
the case of malignant transformation, lymphoid chemokine ex-
pression increases during disease progression (5). The pathways
regulating chemokine expression in SLOs during embryonic life
have been largely described and mainly involve the engagement
of lymphotoxin β receptor on a family of gp38+ lymphoid tissue-
organizer stromal cells (6). At sites of TLO formation, lympho-
toxin and lymphotoxin-producing cells appear to be dispensable
for the early production of lymphoid chemokines required dur-
ing SLO formation, raising the possibility that signals other than
lymphotoxin can regulate the formation of TLOs, stimulating the
production of lymphoid chemokines during inflammation (7, 8).
Some of these signals have been identified in the family of the
IL-23/IL-17 cytokines (9), but other cytokines have been advo-
cated in TLO formation; thus different molecules may play dif-
ferential roles depending on site and nature of the etiological
agent (10).
IL-22, a member of the IL-10 cytokine superfamily, regulates
mucosal responses to danger and wound healing (11). IL-22
promotes tissue repair, inducing epithelial cell proliferation and
survival, in both physiological and pathological conditions (12–
15). Recently, an association between IL-22 expression and au-
toimmune B-cell activation has been proposed (16). In Sjogren’s
syndrome, serum levels of IL-22 correlate with clinical mani-
festations including autoantibody production (17). Furthermore,
B-cell–depleting treatment modulates salivary gland expression
of IL-22, thus suggesting a potential functional relationship be-
tween IL-22 expression, B-cell infiltration, and local pathology
(18). Previously we have demonstrated that direct cannulation of
murine salivary glands with a replication-deficient adenovirus
induces the formation of organized T-cell and B-cell aggregates,
local expression of lymphoid chemokines, and the enzyme aicda
[activation-induced cytidine deaminase (AID)] required for af-
finity maturation and isotype switching in B cells (19). Exploiting
this model, we tested the hypothesis that IL-22 is involved in the
generation of a humoral response within the TLOs (19). Here we
demonstrate that early expression of IL-22 is instrumental for
lymphoid chemokine production by stromal cells that, in turn,
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regulates B-cell aggregation. This work highlights a novel role for
IL-22 in lymphoid chemokine expression and provides a mech-
anistic link between deranged mucosal responses and autoanti-
body production.
Results
Induction of IL-22–Expressing Cells in Murine Salivary Gland TLOs. To
determine whether IL-22 is produced in cannulated salivary
glands, we analyzed mice early post viral cannulation (p.c.). In
WT mice we detected early up-regulation of IL-22 mRNA tran-
script at 3 h p.c., with a second peak of expression at day 5 p.c.
(Fig. 1A). These data were confirmed at the protein level by flow
cytometry analysis of hematopoietic cells isolated from can-
nulated salivary glands. IL-22–producing cells were identified
within the CD45+ cell population by 3 h p.c., with the largest source
of IL-22 [both in terms of percentage of positive cells and mean
fluorescence index (MFI)] deriving from T cells at all time points
examined (Fig. 1 B–D and Fig. S1). At 3 h p.c. IL-22 production
derived largely from γδ T cells, but by day 5 p.c. αβ T lymphocytes
were the main producers of this cytokine (Fig. 1C). Other cell
populations responsible for early IL-22 production were innate
lymphoid cells (ILCs) and natural killer (NK) cells (Fig. 1D).
TLO Formation Is Impaired in the Absence of IL-22. To evaluate the
consequence of IL-22 deficiency in TLO formation and auto-
antibody production, we moved our analysis to Il22−/− mice.
First, resting salivary glands from Il22−/− and WT mice were
evaluated for the presence of potential anatomical or struc-
tural differences that could interfere with virus infectivity. No
differences were found between WT and Il22−/− mice in resting
condition by histological examination and flow cytometry anal-
ysis of the salivary gland epithelial component (Fig. S2 A–C).
Moreover, antiviral responses measured by ELISA showed no
significant differences that could interfere with the establishment
of the model of TLO formation in Il22−/− mice (Fig. S2D).
Histological examination revealed that Il22−/− mice develop
significantly smaller salivary gland lymphocytic aggregates than
WT mice (Fig. 2A). Aggregates in the Il22−/− mice were char-
acterized by a defect in B-cell accumulation (shown as a de-
creased B-cell/T-cell ratio) and follicular organization (Fig. 2 A
and B) as well as a strikingly lower expression of aicda transcripts
(Fig. 2C). This defect was functionally associated with suppres-
sion in autoantibody production (Fig. 2D), suggesting that the
lack of IL-22 impairs B-cell accumulation, organization, and
maturation within TLOs. Interestingly, this defect was not ob-
served in SLOs, where aicda expression was maintained post
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Fig. 1. Source of IL-22 in TLO formation. (A) Quantitative RT-PCR analysis of
mRNA transcript for Il22 in WT mice on day 0, at 3, 6, and 24 h p.c., and on
days 2, 5, 8, 15, and 23 p.c., normalized to β-actin. Relative expression (RQ)
was calibrated to 0 p.c. salivary glands. **P < 0.01; ***P < 0.001 versus day 0.
Results represent two or three experiments with four glands analyzed per
group. (B) Absolute number of IL-22+ cells in the CD45+ population from sal-
ivary glands at 3 h p.c. and on days 2 and 5 p.c. (C) Representative dot plots
identifying IL-22–producing cells in γδ+ T cells (CD3e+gdTCR+NK1.1−CD4−) at
3 h p.c. and in αβ+ T cells (CD3e+gdTCR−NK1.1−CD4+) on day 5 p.c. Data present
the mean ± SD of two different experiments with three salivary glands per
experiment. (D) Distribution of IL-22+ cells in the CD45+ population at 3 h p.c.
and on days 2 and 5 p.c. Data present the mean ± SD from two different
experiments with three salivary glands per experiment.
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Fig. 2. Lack of IL-22 results in defective TLO formation and decreased auto-
antibody production. (A, Left) Salivary gland staining for CD3 (red) and CD19
(blue) in WT and Il22−/−mice at days 8 and 15 p.c. (Right) Lymphoid aggregate
area calculated at days 8 and 15 p.c. for WT (black bars) and Il22−/− (white bars)
mice. Data present the mean ± SD from two different experiments with two or
three mice (four or six salivary glands) per group; **P < 0.01. (B) Ratio between
the CD19+ and CD3+ area at days 8 and 15 p.c. in WT (black bars) and Il22−/−
(white bars) mice. Data present the mean± SD from two different experiments
(four or six salivary glands); **P < 0.01. (C) mRNA transcripts of the aicda gene
(normalized to β-actin), in week 3 p.c. salivary glands fromWT and Il22−/−mice.
RQ values are relative to day 0 p.c. aicdamRNA; data represent the mean ± SD
of three independent experiments with four to six salivary glands analyzed in
each experiment. ***P < 0.001. (D, Left) Autoantibody detection on Hep2 cells
fromWT and Il22−/−mice at week 3 p.c. (nuclear staining in gray, autoantibody
reactivity in green) (serum dilution 1:80). ANA, antinuclear antibody. (Right)
Detection of autoantibody reactivity (percentage of mice positive for auto-
antibody at 1:80 dilution or more) in WT and Il22−/− mice at day 23 p.c. Data
present the mean ± SD of two experiments with five cannulated mice; *P <
0.05; unpaired t test.
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immunization (Fig. S3A). To evaluate the potential contribution
of IL-17 expression to the overall effect observed in the Il22−/−
mice, quantitative PCR was performed on cannulated WT and
Il22−/− mice. Preserved IL-17 up-regulation was observed in
Il22−/− mice p.c., suggesting that the effect on TLO formation in
the Il-22−/− mice is not dependent on IL-17 (Fig. S3B).
IL22−/− Mice Fail to Induce Chemokine (C-X-C Motif) Ligand 13 and
Chemokine (C-X-C Motif) Ligand 12 Expression Within TLOs. To dis-
sect the mechanism by which IL-22 affects B-cell accumula-
tion and response in TLOs, we first evaluated the distribution
of Il-22 receptor α (IL-22Rα) on isolated cell populations
from virus-cannulated salivary glands. As expected, IL-22Rα
expression was restricted to nonhematopoietic (CD45−) cells
(Fig. 3A). IL-22Rα mRNA expression was found on epithelial
cells and on a nonendothelial, nonepithelial stromal cell pop-
ulation positive for gp38 [CD45−epithelial cell adhesion molecule
(EpCAM)−CD31−gp38+], previously demonstrated to produce
lymphoid chemokines during inflammation (20). We therefore
hypothesized that IL-22Rα expression on stromal cells might
contribute to chemokine (C-X-C motif) ligand 13 (CXCL13)
expression in our model, accounting for the decreased B-cell
recruitment observed in Il22− /− mice. Indeed, total mRNA
transcript and protein expression for CXCL13 were significantly
decreased in Il22−/− mice compared with WT mice (Fig. 3B and
Fig. S4). These data were confirmed on sorted gp38+ stromal
cells that showed a significant decrease in the transcript for
CXCL13 in Il22−/− mice (Fig. 3C). In contrast, we observed no
significant difference between WT and Il22−/− mice in CXCL13
expression on sorted epithelial cells or gp38− stromal cells (Fig. 3C).
Next, we investigated another B-cell attractant, chemokine (C-X-C
motif) ligand 12 (CXCL12). Whole-gland mRNA transcript
analysis revealed impaired CXCL12 expression in Il22−/− mice
(Fig. 3D). However, the decrease in CXCL12 expression was
caused by the failure of CXCL12 up-regulation by epithelial cells
rather than by gp38+ stromal cells (Fig. 3E). Taken together,
these findings demonstrate that IL-22 promotes differential
CXCL13 and CXCL12 expression in gp38+/EpCAM− stromal
cells and epithelial stromal cells within TLOs. These findings also
were confirmed in Il22rα−/− mice that showed decreased expres-
sion of the lymphoid chemokines CXCL13 and CXCL12 p.c.,
phenocopying the observation in Il22−/− mice (Fig. S4 B and C).
IL-22 Differentially Induces CXCL13 and CXCL12 Expression in Fibroblastic
and Epithelial Cells in Vitro. To confirm a direct role for IL-22
upstream of CXCL13 and CXCL12 production, we isolated
gp38+ stromal cells and EpCAM+ epithelial cells from WT can-
nulated mice. Incubation of these cells with recombinant IL-22
protein induced the phosphorylation of Stat-3 (downstream
of IL-22Rα signaling) (Fig. 4A). Recombinant IL-22 led to up-
regulation of CXCL13 in gp38+ fibroblasts but not in epithelial
cells (Fig. 4B). In contrast, IL-22 significantly stimulated
CXCL12 expression in epithelial cells but not in fibroblasts
gp38+ 
stromal cells
gp38-
stromal cells
EpCAM+ 
cells
CD45+ cells
D
R
Q
 
N
or
m
al
is
ed
 to
 d
ay
 0
 p
.c
. 
gp
38
-s
tro
m
al
 c
el
ls
cxcl13 mRNA
R
Q
 
N
or
m
al
is
ed
 to
 d
ay
 0
 p
.c
. 
B
A
cxcl12 mRNA
R
Q
 
N
or
m
al
is
ed
 to
 d
ay
 0
 p
.c
. 
R
Q
 
N
or
m
al
is
ed
 to
 d
ay
 0
 p
.c
. 
gp
38
-s
tro
m
al
 c
el
ls
cxcl13 mRNA
C
cxcl12 mRNA
R
Q
 
N
or
m
al
is
ed
 to
 d
ay
 0
 p
.c
. 
gp
38
-s
tro
m
al
 c
el
ls
E
0       5       8       15     23 
days  p.c.  
day 0 p.c.
day 5 p.c.
day 8 p.c.
day 15 p.c.
iI22rα mRNA
8    15       8    15     8     15
gp38+ 
cells
gp38-
cells
EpCAM+ 
cells
*** ***
** *
**
** **
**
**
**
wt
Il22-/-
8    15       8    15     8     15
gp38+ 
cells
gp38-
cells
EpCAM+ 
cells
0       5       8       15     23 
days  p.c.  
wt
Il22-/-
wt
Il22-/-
wt
Il22-/-
** **
* **** ** *
Fig. 3. IL-22–deficient mice fail to induce CXCL13 and CXCL12 expres-
sion within stromal cells of TLOs. (A) Expression of Il22rα mRNA in FACS-
sorted CD45−EpCAM−CD31−gp38+ cells (black bars) in comparison with
CD45−EpCAM−CD31−gp38− cells (white bars), CD45−EpCAM+ epithelial
cells (dark gray bars), and CD45+ cells (light gray bars). Il22rα mRNA
transcripts were assessed by quantitative RT-PCR and normalized to β-actin.
RQ was calculated with day 0 CD45−EpCAM−CD31−gp38− cells as calibrator.
Results represent the mean ± SD of two independent experiments with four
biological replicates. *P < 0.05; **P < 0.01. (B and D) Quantitative PCR
analysis of cxcl13 and cxcl12 mRNA transcripts obtained from salivary glands
at days 5, 8, 15, and 23 p.c. from Il22−/− (white bars) and WT (black bars)
mice. Transcripts were normalized to pdgfrß mRNA; RQ values were calcu-
lated with day 0 salivary gland used as calibrator. **P < 0.01. Data present
the mean ± SD of two independent experiments with two or three mice per
group (four or six salivary glands per experiment). (C and E) mRNA expres-
sion of cxcl13 and cxcl12 mRNA on FACS-sorted CD45−EpCAM−CD31−gp38+,
CD45−EpCAM−CD31−gp38−, and EpCAM+ epithelial cells from WT (black
bars) and Il22−/− (white bars) mice at days 8 and 15 p.c. (normalized to
β-actin), calculated with day 0 CD45−EpCAM−CD31−gp38− cells used as cali-
brator. Data present the mean ± SD of three biological replicates. *P < 0.05,
**P < 0.01; ***P < 0.001.
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Fig. 4. IL-22 induces differential chemokine expression in fibroblasts and
epithelial cells. (A) STAT3 phosphorylation assessed by flow cytometry in
CD45−EpCAM−CD31−gp38+ stroma and EpCAM+ epithelial cells isolated
from salivary glands at day 2 p.c. and stimulated in vitro with IL-22 (blue
lines), IL-22, TNF-α and LTβR agonist (black lines), TNF-α and LTβR agonist (red
lines), or PBS (gray lines). Two independent experiments were performed
with three replicates per experiment. (B and C) Quantitative PCR analysis of
cxcl13 and cxcl12 mRNA from CD45−EpCAM−CD31−gp38+ stromal and
EpCAM+ epithelial cells isolated from salivary glands at day 2 p.c. stimulated
in vitro with IL-22 (black bars), IL-22, TNF-α, and LTβR agonist (gray bars),
TNF-α and LTβR agonist (light brown bars), or PBS (white bars). cxcl13 and
cxcl12 mRNA transcripts were normalized to β-actin mRNA. Results are
presented as RQ values compared with PBS-treated gp38+ stromal cells (B)
or epithelial cells (C ) as calibrator. Data present the mean ± SD of two
independent experiments with three technical replicates per experiment.
**P < 0.01; ***P < 0.001.
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(Fig. 4C). TNF and lymphotoxin, which are known to activate
chemokine expression by stromal cells, also induced Stat3 phos-
phorylation as well as inducing efficient CXCL13 and CXCL12
expression in a manner comparable to IL-22 on its own (Fig. 4 B
and C). Taken together, these data provide a molecular ex-
planation for the defective B-cell accumulation and aberrant
TLO formation observed in the Il22−/− mice, suggesting a novel
role for IL-22 upstream of CXCL12 and CXCL13 expression in
inflammatory conditions at mucosal sites.
Therapeutic Blockade of IL-22 Inhibits Stromal Cell CXCL13 and
CXCL12 Expression and Reduces Autoantibody Production. We next
explored whether therapeutic antibody blockade of IL-22 could
induce regression of TLOs, once formed, and abolish autoanti-
body production, thus reproducing the phenotype observed in
Il22−/− mice. We treated cannulated mice with anti–IL-22 anti-
body blocking starting at either day 2 or day 8 p.c. Immunoflu-
orescence analysis on day 15 p.c. revealed defective lymphoid
aggregate formation, both in terms of TLO size (Fig. 5A) and
B-cell accumulation (Fig. 5 A–C). This effect was more pro-
nounced in mice that were treated from day 2 p.c. than in mice in
which treatment began on day 8 p.c. (Fig. 5 A–C). Quantitative
RT-PCR analysis of the salivary glands from treated mice
showed a strong reduction in the production of both CXCL13
and CXCL12 (Fig. S5). This defect was accompanied by sup-
pression of aicda mRNA transcripts (Fig. S5) that coincided with
a significant decrease in autoantibody production (Fig. 5D),
supporting the concept that IL-22–blocking agents might be
therapeutically effective in clinical practice.
Discussion
IL-22 is known to regulate mucosal homeostasis and promote
epithelial repair following tissue damage (21, 22). Recently, Il-22
has been implicated in malignant epithelial cell proliferation
(23), but its role in chronic inflammation remains enigmatic (15).
Although observational studies have proposed a relationship
between mucosal IL-22 expression and humoral immunity in
humans (18, 24) a direct functional role for IL-22 in ectopic
B-cell activation and TLO formation has not been established. In
this study we explored the hypothesis that IL-22 regulates TLO
development and autoantibody production, influencing the re-
lease of lymphoid chemokines such as CXCL13 and CXCL12
that are critical for TLO assembly. We used a recently described
disease model in which cannulation of the salivary glands with a
replication-deficient adenovirus leads to the formation of TLOs
with breakage of local tolerance and autoantibody production
(19). Here we demonstrate that absence of IL-22 results in
strongly reduced B-cell accumulation within TLOs and signifi-
cant reduction in autoantibodies. This defective autoimmune
response correlates with a failure to induce the B-cell chemo-
attractants CXCL13 and CXCL12 by fibroblasts and epithelial
cells, respectively. The role of IL-22 in a model of lymphoid
organ development has been described previously (25). Ota et al.
(25) reported the ability of IL-22 to restore the organization of
gut-associated lymphoid tissue in mice lacking lymphotoxin sig-
nals. Nonetheless, the authors interpreted their results as sug-
gesting that IL-22 expression is under the control of lymphotoxin
(25). Here we provide evidence that, in vitro, IL-22 can regulate
the production of lymphoid chemokines in fibroblasts, inde-
pendently of lymphotoxin. IL-22 is known to regulate RANKL
expression on synovial fibroblasts from patients with rheumatoid
arthritis via activation of p38 MAPK/NF-κB or JAK-2/STAT-3
signaling (26). Similarly, in our model we demonstrated that
treatment of isolated salivary gland fibroblasts and epithelial
cells with recombinant IL-22 was sufficient to induce STAT3
phosphorylation and production of CXCL13 and CXCL12 in
these two stromal cell populations. Our work and that of Ota
et al. (25) do not exclude the possibility that in vivo, during the
dynamic formation of TLOs, IL-22 and lymphotoxin synergisti-
cally contribute to chemokine production, thus coregulating the
enlargement, organization, and maintenance of the inflamma-
tory aggregates. Strikingly, the induction of IL-22 expression
occurs within hours of salivary gland cannulation and in different
innate immune cell populations. Because Il22−/− mice are char-
acterized by profound defects in early TLO maturation, with
significant loss in lymphoid chemokine expression, we propose
that first resident innate cells and later γδ and αβ T cells, sensing
tissue damage, produce IL-22 to activate stromal cell expression
of B-cell chemokines, thereby allowing the development of
B-cell–rich infiltrates and autoantibody production. The recruit-
ment of IL-22–producing retinoid-related orphan receptor γ
t (RORγt)+natural killer p46 (NKp46)−CD3− CD4+ lymphoid
tissue inducer cells in a CXCL13 transgenic model that mimics
isolated lymphoid follicle formation in the gut has been de-
scribed (27). Taken together, these data suggest that IL-22 plays
a regulatory role in the early phases of lymphoid tissue devel-
opment at mucosal sites. Transgenic expression of lymphoid
chemokines is known to induce TLO formation (8, 28–30).
However, TLOs can form in the absence of RORγt lymphoid
tissue inducer cells (9, 31, 32). This observation suggests that
cytokines present within the inflammatory microenvironment
provide alternative pathways of activation, different from those
A
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Fig. 5. In vivo blockade of IL-22 reverses TLO formation and inhibits auto-
antibody production. (A) Lymphocytic aggregates from WT cannulated sal-
ivary glands from untreated mice, control IgG-treated mice, and mice
treated with anti–IL-22 blocking antibody from day 8 or day 2 p.c. analyzed
at day 15 p.c. for CD3 (red), CD19 (blue), and CXCL13 (green). (B) The ratio
between the area covered by CD19+ B cells and CD3+ T cells at day 15 p.c. for
the conditions above. Data present the mean ± SD of two independent
experiments with two or three mice (four or six salivary glands) per group.
***P < 0.001. (C) Lymphoid follicle size for conditions above calculated as
described inMethods for aggregates at day 15 p.c. Data present the mean ±
SD of two independent experiments with two or three mice (four or six
salivary glands) per group. ***P < 0.001. (D, Left) Immunofluorescent de-
tection of autoantibody on Hep2 cells showing nuclear reactivity in sera at
day 23 p.c. (nuclear staining in gray, autoantibody reactivity in green) (di-
lution 1:80). (Right) Graph summarizing autoantibody reactivity. The data
present the mean ± SD of two experiments with four cannulated mice (bi-
ological replicates expressed as the percentage of mice positive for auto-
antibody at 1:80 dilution or more).
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conventionally associated with physiological lymphoid tissue
formation. A role for IL-17 has been shown in two models of
TLO formation in the lungs (9, 33). Peters et al. (34) also
established the requirement for gp38+ Th17 cells for the devel-
opment of experimental allergic encephalomyelitis in the brain.
We demonstrated in vitro and in vivo that IL-22 is sufficient to
induce chemokine expression. Moreover in Il22−/− mice the
signal for IL-17 is unaffected, thus excluding any significant
contribution of IL-17 in the defect we observed in Il22−/− mice.
Nonetheless, we cannot exclude a combined effect of IL-17 and
IL-22 in TLO development at other sites and under different
conditions. It has been elegantly demonstrated that CXCL13
expression is necessary and sufficient, both in the embryonic life
and at ectopic sites, for the establishment of lymphoid follicles
(28, 29) and the regulation of functional germinal centers (35).
CXCL12 plays a role both in germinal center development and
plasma cell attraction (30, 36). More recently, CXCL12 expres-
sion in nonepithelial stromal cells also has been implicated in
B-cell recruitment to bronchial-associated lymphoid tissue (33).
Carefully dissecting the source of lymphoid chemokines within
TLOs, we have demonstrated that IL-22 exerts an unexpected
differential role in the induction of these two chemokines on
different stromal cell populations. On EpCAM−gp38+ fibro-
blasts, IL-22 stimulation induces CXCL13 expression, both in-
dependently from and additively with TNF- and lymphotoxin β
(LTβ)-receptor signals (known regulators of CXCL13 expres-
sion) (37). Conversely, on EpCAM+ gp38+ epithelial cells, IL-
22Rα engagement by IL-22 is able to increase CXCL12 but not
CXCL13 production. Autoantibody production is the hallmark
of many autoimmune diseases. Autoantibodies have been shown
to precede disease onset, define prognosis, and stratify response
to therapy (38–40). There is convincing evidence that AID ex-
pression on locally activated B cells within TLOs is able to
support class-switch recombination and somatic hypermutation,
thus sustaining affinity maturation of autoreactive B cells to
tissue autoantigens (41, 42). Strikingly, therapeutic blockade of
IL-22 by function-blocking antibodies is sufficient to impair TLO
formation, by preventing organized B-cell aggregation and sig-
nificantly affecting autoantibody production. In this context it is
important to highlight the absence of a defect in aicda up-reg-
ulation in SLOs, further emphasizing the differences between
SLO and TLO biology. Recently it has been shown that exposure
of salivary gland epithelial cells to anti-Ro/SSA and La/SSB
antibodies can induce IL-22 production (43). In agreement with
these in vitro observations, there is evidence that B-cell depletion
following treatment with rituximab leads to decreased expression
of IL-22 in the salivary glands (18). This report suggests the
possibility of a feed-forward loop involving IL-22 expression,
survival of autoreactive B cells, and autoantibody production.
Such an amplificatory loop, dependent on IL-22, also may be
relevant to the well-known but poorly understood association
between Sjogren’s syndrome and the predisposition to B-cell
mucosal-associated lymphoma (41). Previously we have shown
that lymphoma-associated epithelial cells preferentially express
CXCL12, potentially contributing to ductal infiltration and
B-cell survival (5). It is tempting to speculate that, just as excess
production of IL-22 leads to uncontrolled epithelial proliferation
and tumor development in the intestine (42), overproduction
of IL-22 in exocrine glands leads to excessive CXCL12 and
CXCL13 production, contributing to B-cell persistence in TLOs
and lymphoma development. The relationship between TLO
persistence and cancer development is well recognized; for ex-
ample, in the gut the formation of mucosa-associated lymphoid
tissue lymphoma has been associated with excessive CXCL13
expression (44). Our data suggest that IL-22, a critical cytokine
activated in response to mucosal danger signals, provides a
previously unidentified functional link between mucosal auto-
immunity, TLO development, and cancer. Our findings suggest
that targeting the IL-22 pathway might be an effective treatment
in autoimmune diseases characterized by TLO formation. A trans-
lational program involving the use of anti–IL-22 in Sjogren’s
syndrome is currently in development in the Rheumatology Unit
at the University of Birmingham.
Methods
Mice and Salivary Gland Cannulation. C57BL/6micewere purchased fromHarlan.
Il22−/− mice were generated at Lexicon Genetics in collaboration with Pfizer.
Il22Rα1−/−mice were sourced from the European Mouse Mutant Archive, Sanger
Center, United Kingdom. Mice were maintained in the Biomedical Service Unit
at the University of Birmingham according to Home Office and local ethics
committee regulations (University of Birmingham). Submandibular glands of 8- to
12-wk-old female C57BL/6 and knockout mice were intraductally cannulated
with 108–109 pfu of luciferase-encoding replication-defective adenovirus
(Ad5) under anesthesia, as described (19). Animals were culled at specific
time points by terminal anesthesia and cardiac puncture. Salivary glands and
whole blood were harvested. Mice were excluded from the analysis on the
basis of suboptimal virus delivery (Fig. S6) (19).
In Vivo Blocking of Salivary Glands with Anti–IL-22. Rat anti-mouse IL-22 Ab-03
was used as described (45). Starting at either day 2 or day 8 p.c., mice were
administered a dose of 200 μg of anti–IL-22 antibody via i.p injection fol-
lowed by injections three times per week.
Histology and Immunofluorescence. Seven-micrometer sections of salivary
gland were cut by cryosectioning and were stained with directly conjugated
or unconjugated antibodies (SI Flow Cytometry Antibodies). Sections were
mounted using Prolong Gold Antifade reagent (Invitrogen Life Technolo-
gies). Images were acquired on a Zeiss LSM 510 laser-scanning confocal head
with a Zeiss Axio Imager Z1 microscope; LSM510 Image Examiner Software
was used to process the images.
Isolation of Stromal Cells. Harvested salivary glands were cut into small pieces
and tissue digested for 40 min at 37 °C with stirring in 1.5 mL RPMI 1640
medium containing collagenase D (3.7 mg/mL) (Roche), DNase I (30 μg/mL)
(Sigma), and 2% (vol/vol) FCS. The suspension was gently pipetted at 15-min
intervals to break up cell aggregates. Remaining fragments were digested
further for 20 min at 37 °C with medium containing collagenase dispase
(3.7 mg/mL) and DNase I (30 μg/mL). EDTA was added to a final concentra-
tion of 5 mM; then cells were passed through a 70-μm mesh, washed twice,
and resuspended in RPMI 1640 medium containing 10% (vol/vol) FCS.
Isolation of Leukocytes and in Vitro Stimulation for Cytokine Production. After
digestion, cells were resuspended in DMEM [with 10% (vol/vol) FCS, 1%
Glutamine-Penicillin-Streptomycin (GPS) solution, 1% nonessential amino
acids (NEAA), 1% Hepes, and 50 μM β-mercaptoethanol] for in vitro stimu-
lation culture. Isolated cells were incubated with 50 ng/mL phorbol-12-
myristate-13-acetate, 750 ng/mL ionomycin, 10 μg/mL Brefeldin A (all from
Sigma Aldrich), 10 μg/mL recombinant IL-23 (BioLegend), and 10 μL of
108–109 pfu of adenovirus for 4 h at 37 °C.
Flow Cytometry. Single-cell suspensions were incubated with antibodies on
ice for 30 min in PBS (with 0.5% BSA and 2 mM EDTA) with mixtures of
antibodies (SI Flow Cytometry Antibodies). Intracellular staining was per-
formed according to the manufacturer’s protocol (BD Cytofix/Cytoperm).
After surface staining with mixtures of desired antibodies, cells were washed
in PBS (with 0.5% BSA and 2 mM EDTA), resuspended in 150 μL Cytofix/
Cytoperm (BD Pharmingen), and incubated overnight at 4 °C. Cells were
washed twice with the BD Perm/Wash Buffer; then intracellular antibody was
added, and cells were incubated at 4 °C for 30–40 min. Cells were washed
twice, resuspended, and then analyzed using a Cyan-ADP (Dako) with forward/
side scatter gates set to exclude nonviable cells. Data were analyzed with
FlowJo software (Tree Star). For cell sorting, stained cells were sorted using
MoFlo-XDP (Beckman Coulter, Inc.). Sorted cell purity exceeded 96%.
In Vitro Stimulation of Sorted Stromal Cells with Recombinant Cytokines. Iso-
lated stromal cell subsets were resuspended at the same cell density in
500 μL of DMEM [with 10% (vol/vol) FCS, 1% GPS, 1% NEAA, 1% Hepes,
and 50 μM β-mercaptoethanol] in 48-well plates. Recombinant cytokines
were reconstituted in Dulbecco’s phosphate-buffered saline (DPBS) (Sigma
Aldrich). Cells were incubated with 2 μg/mL of recombinant IL-22 (Peprotech)
alone, 2 μg/mL LTβR agonist antibody (Novus Biologicals) plus 500 ng/mL
recombinant TNF-α (Peprotech), 2 μg/mL IL-22 μg/mL plus LTβR agonist
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antibody plus 500 ng/mL TNF-α, or DPBS alone (Sigma Aldrich) for 24 h at 37 °C.
Cells were harvested after 24 h and taken for quantitative PCR analysis.
RNA Isolation and Quantitative PCR. Total RNA was isolated from salivary
glandswith an RNeasymini kit (Qiagen) and reverse-transcribed using the high-
capacity reverse transcription cDNA synthesis kit (Applied Biosystems) on a
Techne 312 Thermal Cycler PCR machine. Quantitative RT-PCR (Applied Bio-
systems) was performed on cDNA samples for cxcl13, cxcl12, aicda, il22rα, il22,
and il17 mRNA expression. β-actin and pdgfrß were used as an endogenous
control. PCR products were detected using an ABI PRISM 7900HT instrument
and were analyzed with the Applied Biosystems SDS software (SDS 2.3) as
described (46). CT values above 34 were not accepted, nor were technical
replicates with more than two cycle differences between them.
Detection of Autoantibodies and Antiviral Response. Hep-2 cells cultured on
slides (IMMCO Diagnostics) were incubated with murine serum diluted in PBS
(1:80). Serawere incubated for 1 h at room temperature, washed twice in PBS,
and incubated with FITC anti-mouse IgG (Sigma) for 30 min. Slides were
washed in PBS, mounted, and analyzed blindly by two different investigators.
Antiviral titer was calculated as already described (19).
Statistical Analysis. Statistical significance was determined by Generalized
Estimating Means (GEE analysis) followed by Sidak’s significance test. In
Figs. 3 A and C and 4 B and C statistical significance was determined by
two-way ANOVA. In Fig. 2D an unpaired t test was used for statistical
significance.
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